Skip to main content
Caplight Logo









Novaremed AG

Novaremed AG

Private
BaselHealthcare & Life Scienceshttps://novaremed.com

Last Round

PIPE

Jan 28, 2021

Company Overview

Novaremed AG operates in Healthcare & Life Sciences and is based in Basel. Its latest recorded funding round was a VC Round in September 2020.

Novaremed AG is a biopharmaceutical company that develops small bio-molecule drugs for the treatment of neuropathic pain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Novaremed AG Comparables

Compare Novaremed AG with similar companies based on industry and business-model similarity.

Novaremed AG comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Plumeria Therapeutics, Inc.
85%
NeuroFront Therapeutics
84%
上海赛默罗生物科技有限公司
83%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Novaremed AG Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
PIPEJan 28, 2021
VC RoundSep 15, 2020
VC RoundSep 2, 2019
VC RoundAug 23, 2018
VC RoundApr 19, 2018
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Pasi Piitulainen

Chief Financial Officer

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 28, 2021

    $50M raised from Gemny.

  • Sep 2, 2019

    Raised $2.63M in a VC Round.

Book a demo to see all signals

For institutional investors. Book with your work email.

Novaremed AG Filings

Explore SEC and related filing metadata, where available.

Novaremed AG filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Novaremed AG's valuation, stock price, and market status.

Is Novaremed AG a public or private company?

Novaremed AG is a private company.

What is the current stock price of Novaremed AG?

Novaremed AG is a private company, so its shares have no public market price. Caplight tracks Novaremed AG's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Novaremed AG worth (valuation)?

Valuation information for Novaremed AG is not publicly available.

Can I buy Novaremed AG stock?

Novaremed AG shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Novaremed AG's last funding round?

Novaremed AG's most recent funding round was PIPE on January 28, 2021.

Who are the main investors in Novaremed AG?

Investor information for Novaremed AG is not publicly disclosed.

Will Novaremed AG IPO soon?

No public IPO plans have been announced for Novaremed AG.

How can I track Novaremed AG secondary market activity?

Caplight tracks bids, offers, and trades in Novaremed AG's shares on secondary markets.

Firmographic Details

HeadquartersBasel
Employee Range5
Year Founded2008
Last FundingJan 28, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?